https://www.biorxiv.org/content/10.1101/2022.05.26.493517v1
SARS-CoV-2 Omicron BA.2.12.1, BA.4, and BA.5 subvariants evolved to extend antibody evasion
Selon Eric Topol:
The immune evasion is more extensive for BA.4/5 than BA.2.12.1 variant, raising the possibility that the former can out-compete the latter. Only one clinically available monoclonal antibody (bebtelovimab) has
full potency against these Omicron subvariants
BA4/BA5 auraient donc tendance à remplacer BA.2.12.1
https://twitter.com/EricTopol/status/1529962992422383617?s=20&t=dfAoiTuZmxPG3zUjJB4ORg